Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peposertib + RT/CRT in Advanced Solid Tumors
NCT02516813Phase 1Completed
- Sponsor
- EMD Serono
- Start
- Sep 2015
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of peposertib in solid tumor (advanced stage), squamous cell carcinoma of the head and neck (HNSCC) and non-small cell lung cancer (NSCLC) (3 arms), sponsored by EMD Serono. Primary endpoint: Dose-limiting Toxicity at 12 weeks. Started Sep 2015; status: completed.
02
Drugs
peposertib
03
Conditions
solid tumor (advanced stage)squamous cell carcinoma of the head and neck (HNSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02516813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02516813.